http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200119009-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02ad4c9403364a2277dc906d5bc5642e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56972 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate | 2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_950066f31ff707599894bf637da59fea |
| publicationDate | 2020-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20200119009-A |
| titleOfInvention | Method of Providing Information for In Vitro Prediction of Anaphylaxis Post Therapeutic Monoclonal Antibody Infusion |
| abstract | The present invention relates to a method for providing information for in vitro prediction of anaphylaxis according to intravenous therapeutic monoclonal antibody, and may occur when intravenous administration of therapeutic monoclonal antibodies in blood cancer and other malignant tumors, rheumatic diseases, and organ transplantation. In order to predict the risk of adverse anaphylaxis side effects in vitro, the risk of the occurrence of anaphylactic side effects is simplified by adding the monoclonal antibody in vitro to the blood collected from the subject and measuring the oxidative ability of the subject's own neutrophils. Can predict quickly. |
| priorityDate | 2019-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.